title: [Short-term safety evaluation of trastuzumab administrated intravenously over 30 minutes with 100 mL saline solution with a focus on infusion reaction].
abstract: In 2011, trastuzumab was approved via public knowledge-based application for administration over 30 minutes from the second round if the first infusion is well tolerated. However, cardiovascular strain and the trastuzumab-specific side effect of infusion reaction induced by an increase in the infusion rate on administering trastuzumab with 250 mL saline over 30 minutes need to be considered. To address these concerns, we evaluated trastuzumab administration with a reduced volume of 100 mL saline over 30 minutes. This method was well tolerated without an increase in the frequency of infusion reaction on retrospective comparison of the 2 administration methods. Thus, administration of trastuzumab with 100 mL of saline over 30 minutes considerably reduces infusion time, benefiting both patients and healthcare providers.
authors: Dept. of Breast Surgery, Hirosaki Municipal Hospital.
authors: Yoshie
authors: Y
authors: Hasegawa
authors: Motomi
authors: M
authors: Miura
authors: Koichi
authors: K
authors: Sato
authors: Yuji
authors: Y
authors: Yamanaka
authors: Junichi
authors: J
authors: Narita
authors: Shigeru
authors: S
authors: Shibata
authors: Takemichi
authors: T
authors: Suto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D012189:Retrospective Studies; D012965:Sodium Chloride; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D012965:Sodium Chloride; D000068878:Trastuzumab